Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

MRI in multiple sclerosis: a review of the current literature.
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis.
Society for Neuroscience Annual Meeting
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Validity and Reliability of a Persian Translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
Medical marijuana: clearing away the smoke.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Ampyra (dalfampridine) medication guide
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
Molecular targets of FTY720 (fingolimod).
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
[Optical coherence tomography in multiple sclerosis].
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.

Pages